RITUXAN Drug Profile

Summary for Tradename: RITUXAN

High Confidence Patents:	24
Applicants:	2
BLAs:	3
Recent Clinical Trials:	See clinical trials for RITUXAN

Recent Clinical Trials for RITUXAN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bristol-Myers Squibb	PHASE1
Nathan Denlinger	PHASE1
Regeneron Pharmaceuticals	Phase 3

See all RITUXAN clinical trials

Pharmacology for RITUXAN

Mechanism of Action	CD20-directed Antibody Interactions
Established Pharmacologic Class	CD20-directed Cytolytic Antibody

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RITUXAN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RITUXAN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,017,732	2034-03-14	DrugPatentWatch analysis and company disclosures
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,336,983	2037-02-09	DrugPatentWatch analysis and company disclosures
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,450,379	2039-04-15	DrugPatentWatch analysis and company disclosures
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,654,940	2039-07-30	DrugPatentWatch analysis and company disclosures
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,662,237	2030-08-06	DrugPatentWatch analysis and company disclosures
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,676,710	2038-06-04	DrugPatentWatch analysis and company disclosures
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	10,759,866	2039-01-04	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for RITUXAN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,004,694	2033-09-12	Patent claims search
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,004,745	2036-03-10	Patent claims search
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,005,783	2037-01-05	Patent claims search
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,016,412	2036-12-09	Patent claims search
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,016,440	2031-04-21	Patent claims search
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	10,017,492	2035-08-27	Patent claims search

International Patents for RITUXAN

Country	Patent Number	Estimated Expiration
Finland	2464725
South Korea	20150024436
South Korea	101782301
South Korea	20180035936
South Africa	201200763
World Intellectual Property Organization (WIPO)	2014145098
Germany	102008013899

Supplementary Protection Certificates for RITUXAN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C02475353/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016
CA 2016 00031	Denmark		PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
122016000049	Germany		PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621
300822	Netherlands		PRODUCT NAME: RITUXIMAB EN RECOMBINANT HUMAAN HYALURONIDASE; REGISTRATION NO/DATE: EU/1/98/067/003 20140326
C02405015/01	Switzerland		PRODUCT NAME: RITUXIMAB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65813 28.06.2016
CR 2016 00031	Denmark		PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; NAT. REG. NO/DATE: EU/1/98/067/003-004 20140326; FIRST REG. NO/DATE: EU EU/1/98/067 20140326
CA 2009 00043	Denmark		PRODUCT NAME: RITUXIMAB; NAT. REG. NO/DATE: EU 1/98/067/001-002 19980602; FIRST REG. NO/DATE: CH IKS 54378 01 19971127

Market Dynamics and Financial Trajectory for RITUXAN

Last updated: March 22, 2026

What is the Current Market Landscape for RITUXAN?

RITUXAN (rituximab), developed by Genentech (a Roche subsidiary), is a monoclonal antibody approved for treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), and certain autoimmune diseases. The drug generated $3.5 billion globally in 2022, with slightly declining sales due to competition and patent expiry.

Key market factors include:

• Patent expiration: Patents for RITUXAN expired in the U.S. in 2018 and in Europe in early 2020.
• Generic and biosimilar entry: Biotech firms introduced biosimilars starting in 2019, notably Pfizer’s Ruxience, Celltrion’s Truxima, and others.
• Efficacy and adoption: RITUXAN remains a first-line treatment for many indications, but biosimilars have eroded market share.
• Regulatory landscape: Regulatory approval of biosimilars varies geographically, impacting market penetration velocity.
• Off-label uses and new indications: Expanding off-label and approved indications influence demand.

How Does RITUXAN Perform in Key Market Segments?

Segment	2022 Revenue (USD bn)	Market Share (2022)	Growth Drivers
Non-Hodgkin lymphoma	$1.2	34%	Established first-line therapy; biosimilars compete
Rheumatoid arthritis	$0.9	26%	Combination therapies; biosimilar uptake
Chronic lymphocytic leukemia	$0.7	20%	Newer agents entering the space
Autoimmune diseases	$0.5	14%	Off-label expansion
Other indications	$0.2	6%	Rare diseases, clinical trials

Market share declined from about 80% pre-patent expiry to approximately 45% in 2022 due to biosimilar competition.

What Are the Financial Trends and Projections?

Year	Estimated Global Revenue	Notes
2022	$3.5 billion	Slight decline compared to 2021, impacted by biosimilars
2023	$2.8 billion	Expected decline due to biosimilars’ market penetration
2024	$2.2 billion	Biosimilar usage stabilizes; off-label growth offsets some decline
2025+	Stabilization at $1.8-$2.0 billion	New indications and combination regimens may contribute to residual sales

Decline rates average 15-20% annually post-patent expiry, but specific trajectories vary by region and indication.

How Do Biosimilar Competitors Affect RITUXAN’s Market?

Biosimilar	Launch Date	Market Share (2022)	Price Reduction	Regulatory Approvals
Ruxience	2019 (US)	25% in US	15-20% off branded	US, Europe, Asia
Truxima	2017 (EU)	20% in EU	10-15% off	US, EU, Asia
Blincyto (investigational biosimilar for specific indications)	-	5%	Pending approval	Pending clinical data

Biosimilar entry has driven pricing and market share erosion, encouraging branded manufacturers to pursue indications expansion and value-added formulations.

What Are Future Revenue Drivers and Risks?

Revenue Drivers:

1. New indications: Approval for diseases like multiple sclerosis or other autoimmune disorders could expand markets.
2. Enhanced formulations: Subcutaneous (SC) formulations improved patient convenience, higher compliance, and potentially increased sales.
3. Combination therapies: Use with novel agents in oncology and autoimmune diseases could sustain demand.
4. Market expansion: Growth in emerging markets with increasing healthcare access.

Risks:

• Patent litigation: Ongoing disputes could delay biosimilar entry or new formulations.
• Regulatory delays: Delays in approval for new indications or formulations impede revenue.
• Pricing pressures: Payer resistance and aggressive biosimilar pricing limit profit margins.
• Competing biologics: Newer agents like obinutuzumab or CAR-T therapies may replace RITUXAN in certain indications.

Strategic Positioning and Lifecycle Management

Genentech relies on:

• Developing SC formulations that reduce administration time.
• Conducting clinical trials for new indications.
• Engaging in patent litigation to extend exclusivity.
• Partnering with biosimilar manufacturers for licensing arrangements.

Key Takeaways

• RITUXAN's revenue peaked pre-patent expiry; current trajectory reflects biosimilar competition and market penetration.
• Future growth depends on expanding indications, formulations, and geographic reach.
• Biosimilars substantially reduce market share and profit margins; strategic innovation mitigates impact.
• Revenue decline is projected at 15-20% annually without significant new indications or formulations.
• Competition from novel biologics and small-molecule agents poses long-term threats.

FAQs

1. Is RITUXAN losing market share to biosimilars?
Yes. Biosimilar introductions since 2019 have reduced RITUXAN’s market share from about 80% to roughly 45% in the U.S. and Europe.

2. Will RITUXAN’s revenue stabilize or increase in the next five years?
Potentially, through new indications, subcutaneous formulations, and expanded uses. However, biosimilar competition remains a significant factor.

3. How crucial are biosimilars in RITUXAN’s revenue decline?
They are a primary factor. Biosimilars account for nearly 50% of the relevant markets post-2019 and continue to erode branded sales.

4. What role do new formulations play?
Subcutaneous formulations can improve patient adherence and reduce administration costs, sustaining some revenue levels.

5. Can RITUXAN maintain its market position without new approvals?
Difficult. Without new indications or formulations, sales are expected to decline steadily due to biosimilar competition and market saturation.

---

Sources

[1] IMS Health. (2022). Global Oncology Market Analysis.
[2] Roche. (2023). RITUXAN Product Information.
[3] FDA. (2022). Biosimilar Approval Summaries.
[4] EvaluatePharma. (2022). Oncology and Autoimmune Drug Market Reports.
[5] IQVIA. (2023). Biologics Market Trends.